Forest’s Namenda Combo Use Rises With Part D, Patent Expirations Loom
Executive Summary
Forest is seeing a strong uptick in combination use of its Alzheimer's therapy Namenda (memantine) as a result of favorable Medicare Part D coverage
You may also be interested in...
Forest Former Chief Scientific Officer Olanoff Returns As President And COO
Lawrence Olanoff will return to Forest Labs as president and chief operating officer following the departure of current President and COO Kenneth Goodman, the company announced Sept. 7
Forest Replants Combunox Sales Force For Pending Beta-Blocker Nebivolol
Forest's plans to distinguish its marketed antihypertensive Benicar and the pending nebivolol include detailing the two products with separate sales forces
NEJM, JAMA Editorials Give Opposing Opinions Of Mandatory HPV Vaccination
Two of the leading medical journals are offering opposing viewpoints on mandatory human papilloma virus vaccination, with experts contributing perspective pieces that directly reflect the larger political and social division over the issue